A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Assessing the Safety and Tolerability
Status:
Withdrawn
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled
study to assess the safety, tolerability and efficacy of two daily doses of oral laquinimod
(0.6mg or 1.2mg) in adjunct to glatiramer acetate (GA) or interferon-beta (IFN-B) in
relapsing remitting multiple sclerosis (RRMS) subjects
Phase:
Phase 2
Details
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc. Teva Pharmaceutical Industries